email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
ChinaBio® Today Articles
Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each. Of course, a subscription is only $20/mo, so you may prefer to subscribe. If so, click on Subscribe in the menu.
Browse
All Products
Articles
All Products
Viewing
391 - 405
of 5508 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
Next
Arctic Vision Starts China Phase III Trial of Farsightedness Therapy
$5.00
Available
ClinChoice, a Global Clinical CRO, Raises $150 Million from China Investors
$5.00
Available
Brii Bio In-licenses China Rights to Second HBV mAb from Vir
$5.00
Available
Ascletis Says PD-L1 Induces “Functional Cure” in CHB Patients
$5.00
Available
Clover Bio’s COVID Vaccine Effective as Booster Against Omicron Variants
$5.00
Available
BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma
$5.00
Available
Suzhou Ascentage to Start US Trial of Novel EED Protein Inhibitor
$5.00
Available
Akeso Approved to Launch Dual Checkpoint Inhibitor for Cervical Cancer
$5.00
Available
GenFleet to Receive Royalty Rights for Conducting China Trial of BioLineRx Cancer Drug
$5.00
Available
Henlius Acquires Two Novel Immunotherapy Candidates in $196.5 Million Deal
$5.00
Available
Shanghai Zai Lab Raises Hong Kong Listing to Primary Status
$5.00
Available
Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug
$5.00
Available
Harbour BioMed to Start US Trials of Novel Bispecific for Solid Tumor Cancers
$5.00
Available
Reistone Completes $100 Million A Round for Inflammatory Disease Drugs
$5.00
Available
Genor Partners with Abogen to Develop mRNA Products for Oncology Needs
$5.00
Available